Skip to main content

Table 1 Group characteristics from Gelman et al., 2012[70]

From: Systems analysis of human brain gene expression: mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimer’s disease

Group (N)

HIV status

Neurocognitive Impairment (GCR)

HIVE

CPE*

Age (years)

PMI (hours)

A (6)

Negative

No (NA)

NA

NA

50 ± 10

19 ± 5.1

B (4)

Positive

No (2.8 ± 1.3)

No

2.1 ± 0.9

50 ± 6.5

11 ± 8.1

C (7)

Positive

Yes (7.1 ± 0.7)

No

1.3 ± 2

44 ± 9.8

7.2 ± 2.1

D (4)

Positive

Yes (8.3 ± 1.7)

Yes

1.8 ± 0.3

44 ± 10

11 ± 4.8

  1. * Note that this grouping schema was used only on one analysis in Study1.
  2. ** CNS Penetration Effectiveness. Higher values indicate greater penetration of antiretroviral medications into brain.